Background: Venom immunotherapy is the only method to radically reduce the risk of a systemic reaction to a Hymenoptera sting. Currently, venom immunotherapy in Poland is generally carried out in a hospital setting. Covering venom extracts with a pharmacy refund, which would allow them to be administered on an outpatient basis could generate savings for the public payer. Methods: Alutard SQ® is in the process of applying for reimbursement for the first time. Due to the progress in negotiations, the price of the drug proposed by MAH, is close to the upper price level of the drug currently available commercially in pharmacies. In this paper, the potential savings for the payer related to drug reimbursement were estimated, taking into account the currently used procedure and drug valuation as well as the expected reimbursement price. The indirect costs and the advantages of the proposed solution for patients were estimated. Results: In the 5-year horizon of the therapy, savings may reach up to PLN 40,000 per patient, which, in the case of 2,000 patients amounts to PLN 80 million. Additionally, potential annual indirect savings related to lost productivity and transportation cost amount to as much as PLN 5 million. Conclusion: Proposed solution would be beneficial for the public payer generating substantial savings as well as patients, whose access to therapy would increase. During COVID-19 epidemy treating patients in ambulatory care would allow avoiding unnecessary contact with hospital care and decrease the risk of infection.